Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213148 | 0.86 | CYP11B2 (0.40) | CYP11B2CYP11B1RIPK2KDM4EALDH1A1 | |
| SCHEMBL17686143 | 0.80 | CYP11B2 (0.47) | CYP11B2CYP11B1GRM2 | |
| SCHEMBL3994597 | 0.79 | SMN1; SMN2 (0.48) | CYP11B2CYP11B1GRM2JAK2KDM4E | |
| SCHEMBL14778515 | 0.78 | KMT2A (0.51) | CYP11B2CYP11B1 | |
| SCHEMBL23269469 | 0.78 | KMT2A (0.46) | GRM2JAK2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL14780364 | 0.77 | L3MBTL1 (0.51) | CYP11B2CYP11B1GRM2 | |
| SCHEMBL29934322 | 0.76 | HRH3 (0.47) | CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL114033 | 0.76 | HRH3 (0.47) | CYP11B2KDM4EALDH1A1HPGD | |
| SCHEMBL17686115 | 0.75 | CYP11B2 (0.46) | CYP11B2CYP11B1RIPK2GRM2PIK3CA | |
| SCHEMBL22770845 | 0.75 | CYP11B2 (0.43) | CYP11B2CYP11B1GRM2PER2CRY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| EP-2991985-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-06-13 | — | — | EP | disclosed |
| US-9745289-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9745289-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| WO-2016061161-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| EP-2991985-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181272-B2 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108026-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, HSD11B1 | CYP11B2 5/4885CYP11B1 2/4885RIPK2 4600/4885 |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, REN | CYP11B2 4/4885CYP11B1 1/4885RIPK2 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.